

Supplementary Appendix: S1:

Comorbidities at enrollment	# of participants	%
Hypertension	123	60.6
Hyperlipidemia	88	43.3
Thyroid		0.0
Hypothyroidism		
• Hypothyroidism	75	36.9
• Hashimoto's disease	4	2.0
• Graves' disease	2	1.0
Microvascular		
• Retinopathy	62	30.5
• Neuropathy	59	29.1
• Nephropathy/Chronic kidney disease	20	9.9
Gastrointestinal	51	25.1
Depression/Anxiety	44	21.7
Cardiovascular		
• Coronary artery disease	40	19.7
• Cerebrovascular	9	4.4
• Peripheral vascular disease	6	3.0
Arthritis	39	19.2
Osteoporosis/Osteopenia	37	18.2
Cataract/Glaucoma	36	17.7
Vitamin D deficiency	32	15.8
Cancer	27	13.3
Dyslipidemia	20	9.9
Functional Activities Questionnaire score, No. (%)**		
• < 8	184	94
• ≥8	12	6

** Score ranges from 0 to 30, with higher scores reflecting greater dependence in instrumental activities of daily living.

Supplementary Appendix: S2:

Candidate variables for discriminating between IAH and NAH.

1. age	2. gender
3. age at the time of diabetes diagnosis	4. duration of diabetes
5. detectable C-peptide	6. randomization arm of BGM or CGM
7. mean glucose, overall	8. mean glucose, daytime
9. mean glucose, night-time	10. % of time spent in hypoglycemia of <70 mg/dL, overall
11. % of time spent in hypoglycemia of <70 mg/dL, daytime	12. % of time spent in hypoglycemia of <70 mg/dL, night-time
13. % of time spent in hypoglycemia of <60 mg/dL, overall	14. % of time spent in hypoglycemia of <60 mg/dL, daytime
15. % of time spent in hypoglycemia of <70 mg/dL, night-time	16. % of time spent in hypoglycemia of <54 mg/dL, overall
17. % of time spent in hypoglycemia of <54 mg/dL, daytime	18. % of time spent in hypoglycemia of <54 mg/dL, night-time
19. % of time spent in range of 70 – 180 mg/dl, overall	20. % of time spent in range of 70 – 180 mg/dl, daytime
21. % of time spent in range of 70 – 180 mg/dl, night-time	22. % of time spent in hyperglycemia >180 mg/dl, overall
23. % of time spent in hyperglycemia >180 mg/dl, daytime	24. % of time spent in hyperglycemia >180 mg/dl, night-time
25. % of time spent in hyperglycemia >250 mg/dl, overall	26. % of time spent in hyperglycemia >250 mg/dl, daytime
27. % of time spent in hyperglycemia >250 mg/dl, night-time	28. % of time spent in hyperglycemia >300 mg/dl, overall
29. % of time spent in hyperglycemia >300 mg/dl, daytime	30. % of time spent in hyperglycemia >300 mg/dl, night-time
31. Hours of CGM data used to calculate metrics, overall	32. Hours of CGM data used to calculate metrics, daytime
33. Hours of CGM data used to calculate metrics, night-time	34. Rate of hypoglycemic events (15 or more consecutive minutes <54 mg/dL) per week, overall
35. Rate of hypoglycemic events (15 or more consecutive minutes <54 mg/dL) per week, daytime	36. Rate of hypoglycemic events (15 or more consecutive minutes <54 mg/dL) per week, night-time
37. Rate of hyperglycemic events per week (15 or more consecutive minutes >300 mg/dL), overall	38. Rate of hyperglycemic events per week (15 or more consecutive minutes >300 mg/dL), daytime
39. Rate of hyperglycemic events per week (15 or more consecutive minutes >300 mg/dL), night-time	40. Coefficient of variation, overall
41. Coefficient of variation, daytime	42. Coefficient of variation, night-time

Candidate variables for discriminating between improvers and non-improvers of IAH	
1. age	2. gender
3. age at the time of diabetes diagnosis	4. duration of diabetes
5. detectable C-peptide	6. randomization arm of BGM or CGM
7. % of time spent in hypoglycemia of <70 mg/dL after 26 weeks, overall	8. % of time spent in hypoglycemia of <70 mg/dL after 26 weeks, daytime
9. % of time spent in hypoglycemia of <70 mg/dL after 26 weeks, night-time	10. % of time spent in hypoglycemia of <54 mg/dL after 26 weeks, overall
11. % of time spent in hypoglycemia of <54 mg/dL after 26 weeks, daytime	12. % of time spent in hypoglycemia of <54 mg/dL after 26 weeks, night-time
13. % of time spent in range of 70 – 180 mg/dl after 26 weeks, overall	14. % of time spent in hyperglycemia >180 mg/dl after 26 weeks, overall
15. % of time spent in hyperglycemia >250 mg/dl after 26 weeks, overall	16. Rate of hypoglycemic events (15 or more consecutive minutes <54 mg/dL) per week after 26 weeks, overall
17. Coefficient of variation after 26 weeks, overall	